ALT5 Sigma Corporation (NASDAQ:ALTS - Get Free Report) was the target of a large increase in short interest during the month of August. As of August 31st, there was short interest totaling 6,800,000 shares, an increase of 220.8% from the August 15th total of 2,120,000 shares. Based on an average daily volume of 6,680,000 shares, the short-interest ratio is presently 1.0 days. Approximately 6.3% of the company's stock are short sold. Approximately 6.3% of the company's stock are short sold. Based on an average daily volume of 6,680,000 shares, the short-interest ratio is presently 1.0 days.
Analyst Ratings Changes
Separately, Wall Street Zen lowered shares of ALT5 Sigma from a "hold" rating to a "strong sell" rating in a research report on Saturday, August 16th.
Read Our Latest Report on ALT5 Sigma
ALT5 Sigma Stock Down 1.8%
NASDAQ ALTS traded down $0.07 on Wednesday, reaching $3.63. The company's stock had a trading volume of 2,902,871 shares, compared to its average volume of 2,768,889. The business has a 50-day moving average price of $6.37 and a 200 day moving average price of $6.47. ALT5 Sigma has a 52 week low of $1.55 and a 52 week high of $10.95. The company has a debt-to-equity ratio of 1.45, a quick ratio of 0.88 and a current ratio of 0.88.
Hedge Funds Weigh In On ALT5 Sigma
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bridgeway Capital Management LLC boosted its position in ALT5 Sigma by 9.4% in the second quarter. Bridgeway Capital Management LLC now owns 19,339 shares of the company's stock valued at $140,000 after buying an additional 1,661 shares in the last quarter. Evernest Financial Advisors LLC acquired a new position in ALT5 Sigma in the second quarter valued at approximately $87,000. Geode Capital Management LLC increased its stake in ALT5 Sigma by 27.6% in the second quarter. Geode Capital Management LLC now owns 194,813 shares of the company's stock valued at $1,412,000 after purchasing an additional 42,157 shares in the last quarter. Finally, Jane Street Group LLC bought a new stake in ALT5 Sigma in the second quarter valued at approximately $380,000. 6.27% of the stock is currently owned by institutional investors and hedge funds.
ALT5 Sigma Company Profile
(
Get Free Report)
ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments.
Recommended Stories
Before you consider ALT5 Sigma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ALT5 Sigma wasn't on the list.
While ALT5 Sigma currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.